Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS

Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its all...
Streetwise Reports | April 27, 2020 |

Valeo Pharma bringing to market drug undergoing clinical trials to improve survival of COVID-19

Valeo Pharma Inc. (CSE: VPH) is a fast-growing revenue generating specialty pharmaceutical company with a strong product portfolio and a robust product pipeline. Valeo Pharma Inc. (CSE: VPH) is a fully integrated specialty pharmaceutical company focused on in-lice...
James O'Rourke | May 22, 2020 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Buzz on the Bullboards: TSX stocks making headlines this week

The TSX experienced a dynamic week. It opened flat on Monday, but saw a significant jump on Tuesday, driven by a global increase in commodity prices following new monetary stimulus measures in China. However, the energy sector’s decline led to a breather...
Jonathon Brown | September 26, 2024 |

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. Early this morning, clinical-stage biopharmaceutical company Deciphera Pharmaceutic...
Streetwise Reports | August 14, 2019 |

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. Eli Lilly and Co. (LLY:NYSE) today annou...
Streetwise Reports | June 17, 2020 |

Concerned About The Real Estate Market? Me Too – Part III

Our continuing research into the state of the Real Estate market suggests the Covid-19 virus event will likely put extreme pressure on many sectors within the US and global markets. This, Part III of a multi-part research article, will highlight many of the key economic data...
Chris Vermeulen | March 24, 2020 |

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. The S&P 500 and NASDAQ have hit fresh highs, a clear sign of a hungry market bolstered by technology stocks. This momentum has put a spot...
Jonathon Brown | June 20, 2024 |

Common Stock Warrants Are a Powerful Wealth Building Tool with Dudley Baker

I recently did this interview with Kerry Lutz and we walk through investment possibilities with mining shares and stock warrants. There is a short advertising break in the middle, so don't leave the interview until completed. Common Stock Warrants Are a Powerful ...
Dudley Pierce Baker | January 30, 2020 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |
1 2 3 4 5